Key Insights

Highlights

Success Rate

81% trial completion

Published Results

192 trials with published results (17%)

Research Maturity

560 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.6%

133 terminated out of 1150 trials

Success Rate

80.8%

-5.7% vs benchmark

Late-Stage Pipeline

19%

217 trials in Phase 3/4

Results Transparency

34%

192 of 560 completed with results

Key Signals

192 with results81% success133 terminated

Data Visualizations

Phase Distribution

821Total
Not Applicable (273)
Early P 1 (12)
P 1 (115)
P 2 (204)
P 3 (137)
P 4 (80)

Trial Status

Completed560
Unknown170
Recruiting141
Terminated133
Active Not Recruiting48
Withdrawn44

Trial Success Rate

80.8%

Benchmark: 86.5%

Based on 560 completed trials

Clinical Trials (1150)

Showing 20 of 20 trials
NCT07619547Not Yet Recruiting

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

NCT07463183Phase 2Recruiting

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT05666960Phase 1Recruiting

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT07185009Phase 3RecruitingPrimary

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06865417Phase 3RecruitingPrimary

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT05767021Phase 3CompletedPrimary

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06581328Phase 4RecruitingPrimary

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

NCT05213234Not ApplicableActive Not RecruitingPrimary

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

NCT07513181Phase 2Not Yet RecruitingPrimary

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT07012395Phase 2RecruitingPrimary

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07501078Phase 2Not Yet RecruitingPrimary

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

NCT04855799Phase 2CompletedPrimary

GI Permeability Change in Response to Aquamin®

NCT05287126Phase 2RecruitingPrimary

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT04033445Phase 2Active Not RecruitingPrimary

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02808780Active Not RecruitingPrimary

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT06515210Not ApplicableRecruitingPrimary

Personalized Anti-Inflammatory Fibres in Ulcerative Colitis

NCT00606346Active Not Recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

NCT00001184Recruiting

Immune Regulation in Ulcerative Colitis or Crohn s Disease

NCT07071519Phase 3RecruitingPrimary

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Scroll to load more

Research Network

Activity Timeline